版本:
中国

BRIEF-Gtx's Enobosarm has been well tolerated among patients

Nov 28 Gtx Inc

* Enobosarm meets pre-specified primary efficacy endpoint in ongoing phase 2 clinical trial in ER+/AR+ breast cancer

* Enobosarm has been well tolerated among patients treated to date in 9 mg dose cohort with majority of adverse events being either grade 1 or 2

* Gtx says plans to report top-line clinical results from these 22 evaluable patients from 9 mg dose cohort in December 2016

* Gtx says expects to report top-line clinical results from full study by middle of 2017, following completion of clinical trial Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐